The BioProtect Balloon Spacer significantly preserves bowel, urinary, and sexual quality of life in prostate cancer patients undergoing radiation therapy over four years. The study showed ...

An expert discusses how proactive referral, multidisciplinary coordination, and early identification can optimize outcomes for patients with muscle-invasive bladder cancer, especially those with ...

TRAVERSE trial showed no increase in MACE with testosterone therapy, improving sexual function and depression symptoms without affecting diabetes or prostate cancer outcomes. T4DM trial found a 13% ...

LUGPA president Scott B. Sellinger, MD, FACS, highlights the key priorities and sessions at this year's LUGPA Annual Meeting. Stay current with the latest urology news and practice-changing insights — ...

Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape. In this interview, conducted at the 2025 LUGPA Annual Meeting, Joshua J. Meeks, ...

DSUI's 2025 report emphasizes advancements in urology through visionary leadership, innovation, and transformative technologies, including AI-powered diagnostics and interdisciplinary research. Dr.

212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy. According to Hansen, 212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy (RLT) being developed for patients with ...

Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC.

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 mg/m2 docetaxel regimen. Despite a higher cumulative docetaxel dose, the 50 ...

Nivolumab significantly improves DFS, OS, and DSS in high-risk muscle-invasive urothelial carcinoma, especially in patients with PD-L1 expression ≥1%. The study's 5-year follow-up confirms nivolumab's ...

Enzalutamide plus leuprolide significantly improves overall survival and metastasis-free survival in biochemically recurrent prostate cancer compared to leuprolide alone. Subgroup analysis revealed ...